INM — InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Q4 2022 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $18.6 million for FY 2022, compared to $10.2 million in FY 2021.
• Loss per Share: $33.17 for FY 2022, down from $37.96 per share in the previous year.
• R&D Expenses: Increased to $7.3 million from $5.3 million, primarily due to the BayMedica acquisition and activities related to the INM-755 Phase 2 trial.
• G&A Expenses: Rose 54% to $6.9 million, attributed to BayMedica's operating results and increased costs associated with being listed on Nasdaq.
• BayMedica Revenue: Generated $1.1 million in sales, reflecting slow growth due to market conditions.
• Cash Position: $6.2 million as of June 30, 2022, with additional funding from a $5.4 million private placement expected to support operations into late FY 2023.

2. Strategic Updates and Business Highlights

• Clinical Trials: Progressing with the Phase 2 trial of INM-755 for epidermolysis bullosa (EB), with nine patients enrolled and the first adolescent patient treated. Data readout anticipated in Q1 2023.
• INM-088 for Glaucoma: Preclinical research is advancing, with plans to file an IND application in H1 2024.
• Neurodegenerative Disease Pipeline: Ongoing exploration of cannabinoid analogs for conditions like Alzheimer's and Parkinson's, with a patent application filed for potential treatments.
• BayMedica Focus: Shifted strategy to reduce commercial activities in the rare cannabinoids market due to slower-than-expected demand and economic pressures.

3. Forward Guidance and Outlook

• Upcoming Catalysts: Expected completion of the Phase 2 trial for INM-755 and data readout in early 2023, IND-enabling toxicology program for INM-088 by end of 2023, and candidate selection for neurodegenerative diseases in Q2 2023.
• Cost-Saving Measures: Implemented a 25% workforce reduction and management salary cuts to reduce annual expenses by approximately 30%.

4. Bad News, Challenges, or Points of Concern

• Market Conditions: Noted significant challenges in the biotech sector, including recessionary pressures and inflation, impacting capital markets and investor sentiment.
• Slow Revenue Growth: BayMedica's revenue growth has been slower than anticipated, leading to a non-cash impairment of $3.5 million in intangible assets.
• Operational Adjustments: Reduced efforts in BayMedica's commercial activities due to market immaturity and competitive pricing pressures.

5. Notable Q&A Insights

• INM-755 Trial: No efficacy data was reported from the independent data monitoring committee; the focus remains on safety and enrollment.
• Future Trials: Eric Adams indicated that additional trials will likely be necessary following the Phase 2 trial of INM-755, as a 20-patient database may not suffice for regulatory filing.
• Burn Rate: Current monthly burn rate is approximately $900,000, expected to decrease to around $700,000, with operational expenses projected at about $500,000 per month.

Overall, InMed Pharmaceuticals is navigating a challenging environment while making strides in its clinical programs and implementing cost-saving measures to sustain operations. The company remains focused on advancing its drug development pipeline despite external pressures.